Bruce Allan Chabner is an American medical oncologist and researcher who worked at the National Cancer Institute and now is a professor of medicine at Harvard Medical School. He is also the director of clinical research at the Cancer Center at Massachusetts General Hospital. His expansive research of cancer pharmacology most notably includes his contributions to developing anti-folate drugs for the treatment of cancer. His work at NIH led to the development of Taxol, a commonly prescribed breast cancer drug.
He completed his undergraduate education at Yale University in 1961 and received his MD from Harvard Medical School in 1965.
Chabner entered the Public Health Service and started working at the National Cancer Institute (NCI) part of the National Institute of Health (NIH), where he studied under Joseph Bertino. His work at NIH led to the development of Taxol, a commonly prescribed breast cancer drug. [1] [2] He left the NIH in 1995 after 27 years at NCI and thirteen years as the director of the division of Cancer Treatment at NCI to join the faculty at Mass General Hospital as chief of hematology and oncology. [3]
He is the director of clinical research at the Cancer Center at Massachusetts General Hospital and professor of medicine at Harvard Medical School.
Chabner grew up in Shelbyville, Illinois as the son of a general practitioner. He is married to Davi‐Ellen Rosenzweig and has two children and five grandchildren. [3]
Vincent Theodore DeVita Jr. is the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, and a Professor of Epidemiology and Public Health. He directed the Yale Cancer Center from 1993 to 2003. He has been president of the board of directors of the American Cancer Society (2012-2013). He is internationally recognized as a pioneer in the field of oncology for his work on combination-chemotherapy treatments.
The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. The EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.
Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.
Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.
Emil J. Freireich was an American hematologist, oncologist, and cancer biologist. He was recognized as a pioneer in the treatment of cancer and use of chemotherapy and is often known as the father of modern leukemia therapy.
Alan D. D'Andrea is an American cancer researcher and the Fuller American Cancer Society Professor of Radiation Oncology at Harvard Medical School. D'Andrea's research at the Dana Farber Cancer Institute focuses on chromosome instability and cancer susceptibility. He is currently the director of the Center for DNA Damage and Repair and the director of the Susan F. Smith Center for Women's Cancer.
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital Yale New Haven Health System, effective February 1, 2022. He also is Deputy Dean for Cancer Research at Yale School of Medicine. From 1997 to 2021, he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, including Chief of Clinical Development, the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.
James Frederick Holland was an American physician and Distinguished Professor of Neoplastic Diseases at the Icahn School of Medicine at Mount Sinai in New York. Early in his career, he had worked for the National Cancer Institute and Roswell Park Comprehensive Cancer Center.
Michael A. Caligiuri is an American physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018. He was previously the CEO of the James Cancer Hospital (2008-2017), Director of the Comprehensive Cancer Center (2003-2017), and Director of the Division of Hematology-Oncology (2000-2008) at the Ohio State University. He was elected to the United States National Academy of Medicine in 2018.
Mary-Ellen Taplin, is a research oncologist at Dana Farber Cancer Institute and Brigham and Women's Hospital in Harvard's Longwood Medical and Academic Area.
Louis Michael Staudt is a scientist at the National Cancer Institute, where he is co-chief of the Lymphoid Malignancies Branch and the director of the Center for Cancer Genomics.
Joseph Rocco Bertino was an American researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research focused on the treatment of lymphoma.
Brigid Gray Leventhal was a British-American pediatric oncologist. She was the first director of the Pediatric Oncology Division at Johns Hopkins University, a position she held from 1976 to 1984. She was inducted into the Maryland Women's Hall of Fame in 1996.
Jung-Min Lee is a South Korean-American medical oncologist and physician-scientist focused on the early clinical drug development and translational studies of targeted agents in BRCA mutation-associated breast or ovarian cancer, high-grade epithelial ovarian cancer, and triple-negative breast cancer. She is a NIH Lasker Clinical Research Scholar and principal investigator in the Women's Malignancies Branch at the National Cancer Institute.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.
Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.
Benjamin Levine Ebert is the Chair of Medical Oncology at the Dana–Farber Cancer Institute and the George P. Canellos, MD and Jean S. Canellos Professor of Medicine at Harvard Medical School.
Sharon A. Savage is an American pediatric hematologist/oncologist. She is the clinical director of the National Cancer Institute's Division of Cancer Epidemiology and Genetics.
Brigitte C. Widemann is German-American pediatric oncologist. She is chief of the pediatric oncology branch and clinical deputy director of the center for cancer research at the National Cancer Institute. She is also the special advisor to the NCI director for childhood cancer.
Neelam K. Giri is an Indian pediatric hematologist/oncologist and physician-scientist who researches bone marrow failure syndromes. She is a staff clinician in the clinical genetics branch at the National Cancer Institute.